The announcement places generic medicines at the center of the administration’s broader effort to increase domestic production of medicines and reduce reliance on foreign supply chains. Generic drugs account for more than 90% of prescriptions filled in the United States, according to the Food and Drug Administration.
A Delayed Tariff Increase Designed to Encourage Domestic Manufacturing
Trump said imported generic drugs will face a 0% tariff starting August 1, 2026, for a two-year transition period. After that period, the tariff would rise to 100% for one year before increasing to 200%.
In a statement posted on Truth Social, Trump said the schedule was designed to give pharmaceutical companies time to move production to the United States. He described the future tariffs as a penalty for companies that choose not to build plants and equipment during the transition period. “The objective of this Policy is to protect the people of the United States,” Trump wrote.
The administration has argued that the country has become too dependent on foreign sources for important medicines and pharmaceutical ingredients. The new tariff plan follows earlier efforts to use trade measures and pricing policies to encourage drugmakers to expand production in the United States.
Trump also said the existing policy covering patented, branded and innovative drugs would remain unchanged. According to the announcement, the rules affecting those categories will continue under the current approach.
The Association for Accessible Medicines, which represents generic drug manufacturers, said it was reviewing details of the proposal. The group’s president and CEO John Murphy III said the industry supports policies that strengthen domestic manufacturing while maintaining access to affordable medicines.
Global Supply Chains Remain Central to Generic Drug Production
The plan could have major implications for international suppliers, particularly India, which plays a significant role in the global generic medicine market. According to CNBC, Indian pharmaceutical companies supply nearly 50% of generic medicines consumed in the United States, while the U.S. represents about one-third of India’s pharmaceutical exports.
Industry analysts said replacing overseas production with domestic manufacturing would be a complex process. Deborah Elms, head of trade policy at the Hinrich Foundation, told CNBC that pharmaceutical production in the United States can be costly and that many manufacturing inputs would still come from abroad.
The supply chain for generic medicines involves more than finished products. Many companies depend on imported active pharmaceutical ingredients, including materials used to produce widely used medicines. China remains a major supplier of some of these upstream components, according to CNBC.
The two-year delay before tariffs begin increasing gives manufacturers time to assess their options, including expanding U.S. facilities, seeking exemptions or adjusting production strategies. Some industry representatives have also pointed to existing challenges involving pricing and reimbursement systems that affect the generic drug sector.
The tariff announcement adds another layer to ongoing discussions between Washington and pharmaceutical companies over drug prices, manufacturing locations and supply chain resilience. The impact of the policy will depend on how companies respond during the transition period before the higher duties are scheduled to take effect.
